

IMMUNALL ANNOUNCES REVOCATION OF CEASE TRADE ORDERS

EDMONTON (Alberta, Canada) February 10, 2016 – Immunall Science Inc. (“**Immunall**” or the “**Company**”) (CSE: GNS) announces that the British Columbia, Alberta, and Ontario securities commissions (collectively, the “**Commissions**”) revoked their respective cease trade orders against Immunall on February 9, 2016.

The Company’s common shares were cease traded by the Commissions for failure to file annual financial statements (the “**Financial Statements**”), management’s discussion and analysis (the “**MD&A**”), and certifications of annual filings (the “**Certifications**”) for the fiscal year ended December 31, 2014. The Company filed the Financial Statements, the MD&A and the Certifications on SEDAR effective July 31, 2015.

On December 23, 2015, the Company amended and restated the MD&A (the “**Amended and Restated MD&A**”), and filed the Amended and Restated MD&A on SEDAR with accompanying certifications of re-filed annual filings (“**Re-filing Certificates**”).

The Financial Statements, the MD&A, the Amended and Restated MD&A, the Certificates and the Re-filing Certificates are all available under the Company’s profile on SEDAR at www.sedar.com.

On behalf of the Board,

M. Frank Phillet
Director & Chief Executive Officer

About Immunall Science Inc.

Immunall Science Inc. (CSE: GNS) is a company incorporated in Alberta and listed on the Canadian Securities Exchange. The Company was involved in researching, developing, and commercializing technology relating to the growth and extraction of American ginseng. In 2014, Immunall ceased these business operations and is currently inactive.

The Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for its adequacy or accuracy

SOURCE: Immunall Science Inc.

For further information:

IMMUNALL SCIENCE INC.

10979 – 127 Street
Edmonton, AB
Canada
T5M 0T1

CO: Immunall Science Inc.